Development of Patient-Derived Tumor Organoids and a Drug Testing Model for Renal Cell Carcinoma

Tumor organoids were developed ex vivo from freshly resected renal cell carcinoma tumors, and their histopathological and molecular characteristics were evaluated using histological staining and whole‑exome sequencing.